UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease

Atherosclerosis, 2016-04, Vol.247, p.48-57

2016

Volltextzugriff (PDF)

Transcriptional Control of Apolipoprotein A-I Gene Expression in Diabetes

Diabetes (New York, N.Y.), 2004-03, Vol.53 (3), p.513-520

2004

Volltextzugriff (PDF)

A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice

Atherosclerosis, 2014-09, Vol.236 (1), p.91-100

2014

Volltextzugriff (PDF)

Combined Expression of Pancreatic Duodenal Homeobox 1 and Islet Factor 1 Induces Immature Enterocytes to Produce Insulin

Diabetes (New York, N.Y.), 2002-05, Vol.51 (5), p.1398-1408

2002

Volltextzugriff (PDF)

Expression of human scavenger receptor B1 on and in human platelets

Arteriosclerosis, thrombosis, and vascular biology, 2003-05, Vol.23 (5), p.898-904

2003

Volltextzugriff (PDF)

Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators

Biomedicine & pharmacotherapy, 2022-08, Vol.152, p.113230-113230, Article 113230

2022

Volltextzugriff (PDF)

Regulation of Scavenger Receptor Class BI Gene Expression by Angiotensin II in Vascular Endothelial Cells

Hypertension (Dallas, Tex. 1979), 2007-06, Vol.49 (6), p.1378-1384

2007

Volltextzugriff (PDF)

Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial

Journal of Alzheimer's disease, 2021-01, Vol.83 (4), p.1703-1715

2021

Volltextzugriff (PDF)

HDL--is it too big to fail?

Nature reviews. Endocrinology, 2013-05, Vol.9 (5), p.308-312

2013

Volltextzugriff (PDF)

Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial

Metabolism, clinical and experimental, 2016-06, Vol.65 (6), p.904-914

2016

Volltextzugriff (PDF)

Obesity-related Changes in High-density Lipoprotein Metabolism

Obesity (Silver Spring, Md.), 2008-06, Vol.16 (6), p.1152-1160

2008

Volltextzugriff (PDF)

The Role of Calcium/Calmodulin-Dependent Protein Kinase Cascade in Glucose Upregulation of Insulin Gene Expression

Diabetes (New York, N.Y.), 2004-06, Vol.53 (6), p.1475-1481

2004

Volltextzugriff (PDF)

Endoplasmic reticulum stress in HepG2 cells inhibits apolipoprotein A-I secretion

Life sciences (1973), 2013-01, Vol.92 (1), p.72-80

2013

Volltextzugriff (PDF)

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease

Cardiovascular therapeutics, 2020, Vol.2020 (2020), p.1-12

2020

Volltextzugriff (PDF)

Corrigendum to “RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease” [Atherosclerosis 247 (2016) 48–57]

Atherosclerosis, 2016-10, Vol.253, p.345-345

2016

Volltextzugriff (PDF)

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

American journal of preventive cardiology, 2022-09, Vol.11, p.100372-100372, Article 100372

2022

Volltextzugriff (PDF)

Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells

Metabolism, clinical and experimental, 2013-02, Vol.62 (2), p.265-274

2013

Volltextzugriff (PDF)

Inhibition of apolipoprotein A-I gene by the aryl hydrocarbon receptor: A potential mechanism for smoking-associated hypoalphalipoproteinemia

Life sciences (1973), 2012-07, Vol.91 (1-2), p.64-69

2012

Volltextzugriff (PDF)

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases

Medicinal research reviews, 2021-01, Vol.41 (1), p.223-245

2021

Volltextzugriff (PDF)

24, 25-Dihydroxycholecalciferol but not 25-hydroxycholecalciferol suppresses apolipoprotein A-I gene expression

Life sciences (1973), 2011-01, Vol.88 (1-2), p.110-116

2011

Volltextzugriff (PDF)

Effect of Chromium on Apolipoprotein A-I Expression in HepG2 Cells

Nutrition (Burbank, Los Angeles County, Calif.), 2003-04, Vol.19 (4), p.353-357

2003

Volltextzugriff (PDF)

Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF α and IL-1β

Biochimica et biophysica acta. General subjects, 2003-10, Vol.1623 (2), p.120-128

2003

Volltextzugriff (PDF)

Platelet derived growth factor regulates ABCA1 expression in vascular smooth muscle cells

FEBS letters, 2006-08, Vol.580 (18), p.4371-4376

2006

Volltextzugriff (PDF)

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection

Cell, 2021-04, Vol.184 (8), p.2167-2182.e22

2021

Volltextzugriff (PDF)

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist

PloS one, 2013-12, Vol.8 (12), p.e83190

2013

Volltextzugriff (PDF)

1 – 25 von 126

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(122)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(126)

Sprache

Englisch
(126)

Erscheinungsjahr

n.n

Thema

Science & Technology
(100)
Life Sciences & Biomedicine
(98)
Humans
(70)
Animals
(54)
Biological And Medical Sciences
(39)
Male
(32)
Rats
(32)
Apolipoprotein A-I - Genetics
(31)
Biochemistry & Molecular Biology
(29)
Endocrinology & Metabolism
(24)
Fundamental And Applied Biological Sciences. Psychology
(24)
Promoter Regions, Genetic
(21)
Gene Expression
(20)
Pharmacology & Pharmacy
(19)
Rna, Messenger - Metabolism
(19)
Proteins
(18)
Cardiovascular Disease
(17)
Liver - Metabolism
(17)
Transfection
(17)
Atherosclerosis
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease

Transcriptional Control of Apolipoprotein A-I Gene Expression in Diabetes

A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice

Combined Expression of Pancreatic Duodenal Homeobox 1 and Islet Factor 1 Induces Immature Enterocytes to Produce Insulin

Expression of human scavenger receptor B1 on and in human platelets

Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators

Regulation of Scavenger Receptor Class BI Gene Expression by Angiotensin II in Vascular Endothelial Cells

Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial

HDL--is it too big to fail?

Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial

Obesity-related Changes in High-density Lipoprotein Metabolism

The Role of Calcium/Calmodulin-Dependent Protein Kinase Cascade in Glucose Upregulation of Insulin Gene Expression

Endoplasmic reticulum stress in HepG2 cells inhibits apolipoprotein A-I secretion

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease

Corrigendum to “RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease” [Atherosclerosis 247 (2016) 48–57]

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells

Inhibition of apolipoprotein A-I gene by the aryl hydrocarbon receptor: A potential mechanism for smoking-associated hypoalphalipoproteinemia

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases

24, 25-Dihydroxycholecalciferol but not 25-hydroxycholecalciferol suppresses apolipoprotein A-I gene expression

Effect of Chromium on Apolipoprotein A-I Expression in HepG2 Cells

Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF α and IL-1β

Platelet derived growth factor regulates ABCA1 expression in vascular smooth muscle cells

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist

Suchergebnisse filtern